Your browser doesn't support javascript.
loading
A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?
Lodise, Thomas P; Zhao, Qi; Fahrbach, Kyle; Gillard, Patrick J; Martin, Amber.
Afiliación
  • Lodise TP; Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
  • Zhao Q; Global Health Economics and Outcomes Research, Allergan plc, Madison, NJ, USA.
  • Fahrbach K; Meta Research, Evidera, Bethesda, MD, USA.
  • Gillard PJ; Global Health Economics and Outcomes Research, Allergan plc, 2525 Dupont Drive, Irvine, CA, 92612, USA. gillard_patrick@allergan.com.
  • Martin A; Meta Research, Evidera, Bethesda, MD, USA.
BMC Infect Dis ; 18(1): 625, 2018 Dec 05.
Article en En | MEDLINE | ID: mdl-30518337
ABSTRACT

BACKGROUND:

Temporal relationships between the time to appropriate antibiotic therapy and outcomes are not well described.

METHODS:

A systematic literature review and meta-analysis was performed to examine this relationship in patients hospitalized with Klebsiella pneumoniae or Escherichia coli infections.

RESULTS:

Twenty identified studies contained data for patients who received delayed appropriate therapy (DAT) versus appropriate antibiotic therapy for these pathogens. Of the 20 included studies, the majority (19/20) focused on patients with bloodstream infections, and only 1 study evaluated patients with pneumonia. When all DAT results were combined (any delay > 24 h from culture collection or any delay after culture and susceptibility reporting [C& SR]), there was an increased risk of mortality (odds ratio [OR], 1.60 [95% CI, 1.25-2.50]). The risk of mortality was greater when DAT > 48 h from culture collection or DAT > C&SR results were combined (OR, 1.76 [95% CI, 1.27-2.44]).

CONCLUSIONS:

Our findings suggest there is a need to shift current treatment practices away from antibiotic escalation strategies that contribute to delayed appropriate therapy and toward early, relatively aggressive and comprehensive, antibiotic therapy, especially among patients with bloodstream infections due to K. pneumoniae or E. coli.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Klebsiella / Mortalidad Hospitalaria / Infecciones por Escherichia coli / Tiempo de Tratamiento / Antiinfecciosos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Klebsiella / Mortalidad Hospitalaria / Infecciones por Escherichia coli / Tiempo de Tratamiento / Antiinfecciosos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos